Prosecution Insights
Last updated: August 06, 2026

Sirnaomics Inc.

8 pending office actions • 5 art units • 7 examiners • 0 of 8 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Portfolio Summary

8
Total Pending OAs
4
Non-Final OAs
4
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
1
Due this week
2
Due this month
1
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (1)Due ≤ 7 days (1)Due ≤ 30 days (2)Due ≤ 60 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

4
Hard (50%)
4
Medium (50%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only3 (38%)
Double-patenting + other1 (12%)
Multi-statute (no §101)4 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

8
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

80 h
Manual time on pending OAs
16 h
Time saved (low, 20%)
28 h
Time saved (mid, 35%)
0.7 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
YU, DELPHINUS DOU YI 2 50.0% +0.0%
HUDSON, AMY ROSE 1 75.0% +11.4%
POLIAKOVA-GEORGAN, EKATERINA 1 64.1% +17.8%
GIBBS, TERRA C 1 63.9% +10.4%
ARIETI, RUTH SOPHIA 1 45.3% +72.1%
COHEN, MICHAEL P 1 58.7% +27.2%
GREENE, IVAN A 1 18.7% +6.2%

Hard Cases (5)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
17951842 METHODS FOR PREPARING NANOPARTICLE COMPOSITIONS CONTAINING HISTIDINE-LYSINE COPOLYMERS YU, DELPHINUS DOU YI 17d overdue
18179410 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PCSK9 GIBBS, TERRA C 6d
18126145 NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES POLIAKOVA-GEORGAN, EKATERINA 9d
17935022 NANOPARTICLE PHARMACEUTICAL COMPOSITIONS WITH REDUCED NANOPARTICLE SIZE AND IMPROVED POLYDISPERSITY INDEX GREENE, IVAN A 22d
18355280 METHODS FOR INDUCING ADIPOSE TISSUE REMODELING USING RNAI THERAPEUTICS HUDSON, AMY ROSE

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18179410 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PCSK9 GIBBS, TERRA C 6d
18126145 NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES POLIAKOVA-GEORGAN, EKATERINA 9d
18355280 METHODS FOR INDUCING ADIPOSE TISSUE REMODELING USING RNAI THERAPEUTICS HUDSON, AMY ROSE
18170971 PRODUCTS AND COMPOSITIONS ARIETI, RUTH SOPHIA
17935014 NANOPARTICLE FORMULATIONS FORMED FROM HISTIDINE-LYSINE COPOLYMERS COHEN, MICHAEL P

Top Art Units

Art UnitApps
1636 3
1635 2
1637 1
1612 1
1619 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18495687 SIRNAS AGAINST KRAS AND RAF1 YU, DELPHINUS DOU YI 1636 §103 Non-Final OA 54d Pending Oct 26, 2023
18355280 METHODS FOR INDUCING ADIPOSE TISSUE REMODELING USING RNAI THERAPEUTICS HUDSON, AMY ROSE 1636 §103§112 Final Rejection Pending Jul 19, 2023
18126145 NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES POLIAKOVA-GEORGAN, EKATERINA 1637 §102§103Other Non-Final OA 9d Pending Mar 24, 2023
18179410 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PCSK9 GIBBS, TERRA C 1635 §103§112Other Final Rejection 6d Pending Mar 07, 2023
18170971 PRODUCTS AND COMPOSITIONS ARIETI, RUTH SOPHIA 1635 §103§112DP Non-Final OA Pending Feb 17, 2023
17935014 NANOPARTICLE FORMULATIONS FORMED FROM HISTIDINE-LYSINE COPOLYMERS COHEN, MICHAEL P 1612 §103 Final Rejection Pending Sep 23, 2022
17951842 METHODS FOR PREPARING NANOPARTICLE COMPOSITIONS CONTAINING HISTIDINE-LYSINE COPOLYMERS YU, DELPHINUS DOU YI 1636 §103§112 Non-Final OA 17d overdue Pending Sep 23, 2022
17935022 NANOPARTICLE PHARMACEUTICAL COMPOSITIONS WITH REDUCED NANOPARTICLE SIZE AND IMPROVED POLYDISPERSITY INDEX GREENE, IVAN A 1619 §103Other Final Rejection 22d Pending Sep 23, 2022

Managing Sirnaomics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month